New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2013
16:30 EDTAMRNAmarin believes Vascepa well positioned in triglyceride lowering market
Amarin believes that Vascepa is well positioned to compete in the triglyceride lowering market. This is a large market which, based on market research, Amarin believes is currently underpenetrated due to limitations of existing therapies. Amarin's market research further suggests that clinicians value the data supporting Vascepa in the MARINE indication: in patients with very high (=500 mg/dL) triglyceride levels, Vascepa has been shown to lower triglycerides without increasing bad cholesterol (low-density lipoprotein cholesterol, or LDL-C) and with a tolerability and safety profile similar to placebo. Amarin formally launched Vascepa in the United States on January 28.
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:17 EDTAMRNAmarin announces two presentations on EPA dyslipidemia studies
Amarin announced the presentation of findings from two studies, a retrospective study in which patients were switched from an EPA plus DHA combination product to EPA-only Vascepa as well as a sub-analysis of the ANCHOR clinical trial, at two key cardiovascular meetings. The EPA+DHA to EPA-only switch study investigated the effect of EPA-only omega-3 therapy compared to EPA+DHA therapy on multiple patient lipid parameters. Results of this case series showed a reduction in both triglyceride and low-density lipoprotein cholesterol levels with EPA-only therapy in most of these high-risk statin-treated patients. The ANCHOR sub-analysis is an encore presentation which examined the effect of EPA on high-risk statin-treated patients with persistently high triglyceride levels, showing that icosapent ethyl increased EPA in plasma and red blood cells in a linear, dose-dependent fashion consistent with its triglyceride-lowering effect.
July 24, 2015
16:38 EDTAMRNAmarin files to sell 38.9M series A preference shares in form of ADS for holders
Subscribe for More Information
16:34 EDTAMRNAmarin files to sell 3.89M ordinary shares in form of ADS for holders
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use